Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK-0045 in overweight/obese participants with type 2 diabetes
NCT06611930Phase 2Terminated
- Sponsor
- Cytoki Pharma
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Carrier/Scaffold Proteins, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CK-0045 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Cytoki Pharma. Primary endpoint: Area under the plasma glucose curve after a Mixed Meal Tolerance Test at 16 weeks. Started Sep 2024; status: terminated.
02
Drugs
CK-0045
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06611930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611930.